Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure

Transplantation and Cellular Therapy(2023)10.1016/j.jtct.2023.06.019Source: DataRank Database

Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure is a research paper published in Transplantation and Cellular Therapy (2023). On theSindex it has a DataRank of 0.370. It has been cited 6 times, with 5 citing works in its 1-hop citation network.

N/A

0.370DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access6 citations · 5 citing works in its network

Download PDF

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT03827343

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 0.68)OA: hybridTopics (43)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 79%Citation Network 21%

Base Score Contribution

0.292

From this paper's citation signal

Citation Network Contribution

0.0784

From 4 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 5 citers.

Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Cancer Discovery20253 citations35 referencesContributes 0.040
Allogeneic transplantation after immunotherapy for relapsed/refractory non-Hodgkin lymphoma: a comparison with a historical cohort
Cytotherapy20245 citations53 referencesContributes 0.034
Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications
Heliyon20242 citations88 referencesContributes 0.012
Broadening the horizon: potential applications of CAR-T cells beyond current indications
Frontiers in Immunology202314 citations424 referencesContributes 0.006
Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T - cell persistence in ALL
Hematology20250 citations61 referencesContributes 0.000

Authors (16)

Bonnie Yates,Seth M. Steinberg ORCID,Constance M. Yuan ORCID,Hao‐Wei Wang ORCID,Colleen Annesley ORCID

Live enrichment

PubMed:37394115 OpenAlex:https://openalex.org/W4382700748

National Institutes of Health

Grant: ZIA BC 011823

FWCI

0.68

Citation Percentile

0.7%

Citation Trend

2023

2024

2025

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.jtct.2023.06.019

HYBRIDhttps://doi.org/10.1016/j.jtct.2023.06.019

publisherhttps://doi.org/10.1016/j.jtct.2023.06.019

publisherhttps://api.elsevier.com/content/article/PII:S2666636723013787?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666636723013787?httpAccept=text/plain

Fields of Study

CAR-T cell therapy researchAdvancements in Semiconductor Devices and Circuit DesignIntegrated Circuits and Semiconductor Failure AnalysisMedicineChildYoung AdultHumansChild, PreschoolAdolescentAdultReceptors, Chimeric AntigenT-LymphocytesSalvage TherapyImmunotherapy, AdoptivePrecursor B-Cell Lymphoblastic Leukemia-LymphomaRecurrence

MeSH Terms

Receptors, Chimeric AntigenAdolescentAdultChildChild, PreschoolHumansRecurrenceT-LymphocytesPrecursor B-Cell Lymphoblastic Leukemia-LymphomaImmunotherapy, AdoptiveSalvage TherapyYoung Adult

Keywords

CartChimeric antigen receptorMedicineCD19Internal medicineAntigenT cellImmunologyOncologyImmune systemAcute lymphoblastic leukemiaChimeric antigen receptor T cellsImmunotherapyRelapseSalvage therapy

Sustainable Development Goals

SDG 0: No poverty